Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Inovio Pharmaceuticals, Inc.

NASDAQ: INO · Life Sciences · 5 alerts · CIK 1055726

Share price
$1.40Close, Nov 16
Market cap
$262M
Shares outstanding
187.31MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Inovio Pharmaceuticals, Inc. filings on SEC EDGAR ↗

7:30 AM ET 8-K
Capital Raise

Inovio Pharmaceuticals Capital Raise of $80.5M

INOVIO Pharmaceuticals entered into an underwriting agreement for a public offering of 58,747,235 shares of common stock and 12,681,337 pre-funded warrants. The underwriters fully exercised their option to purchase an additional 10,714,285 shares, bringing expected net proceeds to approximately $80.5 million. The capital will be used to support the company's development and commercialization of DNA medicines.

Value
$80.5M
Counterparty
Jefferies LLC and Piper Sandler & Co.
7:15 AM ET 8-K
Regulatory Approval

Inovio Pharmaceuticals Regulatory Approval

The FDA granted accelerated approval for INOVIO's VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP). This represents the first U.S. FDA-approved DNA medicine and validates INOVIO's platform technology, with a commercial launch expected in Q1 2027.

“With the approval of VOCERYQ, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option. VOCERYQ is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.